Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Short term Debt: 2018-2025

  • China SXT Pharmaceuticals' Short term Debt fell 99.94% to $4,475 in Q3 2025 from the same period last year, while for Sep 2025 it was $4,475, marking a year-over-year decrease of 99.94%. This contributed to the annual value of $702,184 for FY2025, which is 42.42% up from last year.
  • According to the latest figures from Q3 2025, China SXT Pharmaceuticals' Short term Debt is $4,475, which was down 99.36% from $702,184 recorded in Q1 2025.
  • China SXT Pharmaceuticals' Short term Debt's 5-year high stood at $12.1 million during Q1 2021, with a 5-year trough of $4,475 in Q3 2025.
  • Moreover, its 3-year median value for Short term Debt was $457,111 (2023), whereas its average is $1.5 million.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Short term Debt soared by 1,668.20% in 2024 and then crashed by 99.94% in 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Short term Debt (Quarterly) stood at $2.1 million in 2021, then plummeted by 43.04% to $1.2 million in 2022, then slumped by 65.08% to $421,168 in 2023, then skyrocketed by 1,668.20% to $7.4 million in 2024, then tumbled by 99.94% to $4,475 in 2025.
  • Its last three reported values are $4,475 in Q3 2025, $702,184 for Q1 2025, and $7.4 million during Q3 2024.